A Ludwig Cancer Research study has identified a specific mode of fat uptake by immune cells within tumors that serves as a metabolic checkpoint against anti-cancer immune responses.

According to the results of the early study, published simultaneously in the New England Journal of Medicine, 92% of patients ...

For patients with cancers harboring certain genetic defects, the first-in-class targeted therapy RO7589831, which targets the ...

Researchers have identified a compound that could block certain life-threatening and hard-to-treat allergic reactions.

There have been new developments in treatments for chronic spontaneous urticaria, with dupilumab, remibrutinib, and ...

A Ludwig Cancer Research study has identified a novel strategy for treating acute myelogenous leukemia (AML), an aggressive ...

Masitinib is an inhibitor of KIT, LYN, and FYN, three major kinases involved in the activation of mast cells and basophils. The classic view of sickle cell disease pathophysiology involves ...

When mast cells accumulate with SM ... Note that this medication is an oral wild-type KIT inhibitor that demonstrated a positive safety profile with dose-dependent effects on the serum tryptase ...

Their final analysis supports belzutifan as a treatment option in advanced clear cell RCC after PD-L1/PD-1 inhibitor and vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGF-TKI ...

Arcus Biosciences Inc. has disclosed mast/stem cell growth factor receptor Kit (KIT; c-Kit; CD117) inhibitors reported to be useful for the treatment of cancer, allergy, autoimmune, inflammatory, ...